Sandoz Group AG reported first-half 2026 net sales of $5,761 million, a 10% increase from the prior year. Biosimilars contributed $1,875 million, up 25% and now representing 33% of total net sales, while generics delivered $3,886 million, a 4% rise. Core EBITDA grew 15% to $1,206 million with margin expansion to 20.9%, and core diluted EPS increased 17% to $1.71. The company reaffirmed its full-year guidance for mid-to-high single-digit net sales growth at constant currencies and approximately 100 basis points of core-EBITDA margin expansion, and added four new biosimilar assets to its pipeline, bringing the total to 36.
Sandoz Group AGStrong H1 results with 10% sales growth, 25% biosimilar growth, and raised margin guidance.
